RxDoctor Payments Data

Hong-I Shen, MD

Family Medicine · Longview, TXNPI 1700866969

Payments from drug & device makers

$1,185in general payments, 2019–2025

Across 98 payments — averaging $12.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$564
  • AbbVie$105
  • Johnson & Johnson$98
  • Lilly USA, LLC$91
  • Sanofi-aventis U.S. LLC$55
  • Otsuka America Pharmaceutical, Inc.$47
  • plus $225 from 12 others

What the payments were for

  • Food & beverage$1,14597%
  • Education$403%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,185 in reported general payments places this provider in the 60th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$209,179
Medicare patients
521
Services billed
2,894

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban982$317,877
IngrezzaValbenazine Tosylate30$114,458
JardianceEmpagliflozin219$79,196
XareltoRivaroxaban169$59,720
MyrbetriqMirabegron210$59,691
TrulicityDulaglutide52$54,948
AustedoDeutetrabenazine11$39,211
LinzessLinaclotide45$35,675
OzempicSemaglutide35$35,475
MounjaroTirzepatide31$35,102
JanuviaSitagliptin Phosphate107$34,346
Potassium Chloride946$31,781
FarxigaDapagliflozin Propanediol73$29,193
NuedextaDextromethorphan Hbr/Quinidine38$29,083
EntrestoSacubitril/Valsartan66$23,268

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$317,877982 claims
Neurocrine Biosciences, Inc.Ingrezza$15$114,45830 claims
Lilly USA, LLCTrulicity, Mounjaro$91$90,05083 claims
Johnson & JohnsonXarelto$98$59,720169 claims
AbbVieLinzess, Vraylar$105$52,10070 claims
Teva Pharmaceuticals USA, Inc.Austedo$27$39,21111 claims
Novo NordiskOzempic$564$35,47535 claims
AstraZenecaFarxiga$27$29,19373 claims
Avanir Pharmaceuticals, Inc.Nuedexta$13$29,08338 claims
NovartisEntresto$12$23,26866 claims
Sanofi-aventis U.S. LLCMultaq$55$17,89345 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Longview

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →